很抱歉,您的瀏覽器過於老舊無法閱讀網頁內容的需要,請更新瀏覽器或安裝 Google Chrome.
Bringing Hope to Life
Bringing Hope to Life
Senhwa is a precision therapy company focusing on developing First-in-Class therapeutics for patients with unmet medical needs. These include multiple programs for gene-mutated cancers, rare diseases, and novel coronaviruses.
OUR PIPELINE
Coronavirus Curative
Coronavirus Curative
The first patient treated with Senhwa’s Silmitasertib (CX-4945) for severe COVID-19 demonstrated remarkable recovery and was discharged in 5 days after treatment.
OUR CLINICAL TRIALS
One Drug with Multi-target Therapy
One Drug with Multi-target Therapy
Senhwa’s Pidnarulex (CX-5461) has proven to be the next generation DDR (DNA Damage Response) drug, with the mechanism of synthetic lethality across multiple tumor types in patients with loss of function of tumor suppressor genes such as HRD (Homologous Recombination Deficiency) and beyond, and has great potential for patients who have developed resistance to PARP inhibitors and platinum or other chemotherapies.
OUR PLATFORM
Pioneering the Paradigm
Pioneering the Paradigm
Senhwa strives to design and develop innovative therapies rooted in our leading expertise in protein kinases inhibition, and improve quality of life for cancer patients. .
OUR COMPANY

Latest News

September 10, 2021
Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations
August 31, 2021
Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

Media and Events

September 10, 2021
Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations
August 31, 2021
Senhwa's Silmitasertib, COVID-19 Drug Candidate, Receives Positive Interim Review from Data Monitoring Committee to Proceed

Senhwa Biosciences' drug product, Silmitasertib (CX-4945), blocks CK2- potentially stopping SARS-Cov-2 in its tracks

Clinical Programs

Publications

Protein kinase CK2: a potential therapeutic target for diverse human diseases

OUR VISION

“As a value added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical Proof of Concept”
- Dr. Tai-Sen Soong, President/CEO

MEET THE SENHWA TEAM

John Soong, Chief Medical Officer

Dr. John Soong is a board certified physician with specialty training in Clinical Pathology and a Fellow of the College of American Pathologists (FCAP). His experiences in patient care as well as expertise in diagnosing a broad spectrum of human diseases through the understanding of disease mechanisms brings insights to novel drug target identification.